White Paper

Calculating Your Business Case For Pharmaceutical Continuous Manufacturing

By Richard Steiner, senior manager, business strategy, Pharmatech Associates


Development and commercialization of a drug product in a highly regulated market involves a significant amount of risk. Advanced manufacturing processes such as pharmaceutical continuous manufacturing (PCM) introduces additional risk to the drug life cycle and is often a barrier to implementing any new technology.

Review key considerations as a Pharmatech Associates expert introduces a useful financial equation to calculate amortization to develop the business case for PCM and provides a few real-world cases. Discover how PCM can support specific business needs and how to implement it.

access the White Paper!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Cell & Gene? Subscribe today.

Subscribe to Cell & Gene X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Cell & Gene

Pharmatech Associates - A USP Company